---
title: "Weekly Recap | CME +3.95%, closing in on record highs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305533944.md"
description: "CME rose 3.95% this week to close at $317.97, outperforming the S&P 500 by roughly 1.44 percentage points (the benchmark added 2.51%). The move was choppy at first: Monday opened weak and traded down to $300.58, then the stock climbed into the middle of the week. Thursday touched an all-time high of $321.335 before Friday settled back to $317.97. Weekly amplitude was 6.8% on roughly average volume."
datetime: "2026-11-14T06:12:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305533944.md)
  - [en](https://longbridge.com/en/news/305533944.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305533944.md)
generator: "portal-rs"
---

# Weekly Recap | CME +3.95%, closing in on record highs

## The Week

CME rose 3.95% this week to close at $317.97, outperforming the S&P 500 by roughly 1.44 percentage points (the benchmark added 2.51%). The move was choppy at first: Monday opened weak and traded down to $300.58, then the stock climbed into the middle of the week. Thursday touched an all-time high of $321.335 before Friday settled back to $317.97. Weekly amplitude was 6.8% on roughly average volume.

## Key Events

The week centred on record trading volumes and new contract initiatives. On Wednesday 11 November, CME set a new volume record in lean hog futures and options, while reports said the CFTC delayed approval of futures contracts tied to AI chip rental prices. On Thursday 12 November, CME was said to be planning a physically backed uranium futures contract, and the stock hit a record intraday high the same day. Monday saw Chief Commercial Officer Julie Winkler sell a batch of shares, and the Trump administration’s embrace of perpetual futures raised risk alarms among Wall Street stalwarts. The company-specific thread was mainly product expansion and volume strength.

## Analyst Ratings

Of the 19 institutions covering CME, 4 rate it buy, 5 rate it overweight, 6 rate it hold, 1 rates it underweight and 1 rates it sell, with 2 having no opinion. The consensus rating is buy. The consensus target price of $317.0625 sits about 0.29% below the latest price of $317.97; the target range runs from $227 to $367, showing wide dispersion. CME ranks 6th out of 26 in its industry.

## The Week Ahead

A dense run of US macro data lands next week: the New York Fed manufacturing index on Monday 16 November, followed on Tuesday 17 November by retail sales, import prices, industrial production and the NAHB housing market index. CME’s next earnings release is scheduled for 10 February 2027 before the open, covering fiscal Q4 2026, with consensus estimates of $2.8515 EPS and $1.762 billion in revenue.

## In Short

CME gained 3.95% this week and briefly set an all-time high, with product innovation and record volumes as the main narrative. The consensus rating is buy, but the consensus target sits near the spot price and the target range is unusually wide, suggesting analysts’ views on further upside are mixed. On the latest trading day, large-lot money was a net buyer while small and medium lots were net sellers, leaving a divided flow picture. The next things to watch are whether macro data sustains risk appetite and whether uranium or AI chip-related futures products translate into fresh volume catalysts.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [CME.US](https://longbridge.com/en/quote/CME.US.md)

## Related News & Research

- [Uniswap’s retail demand returns after 2 weeks of losses: Can UNI defend $6.80?](https://longbridge.com/en/news/301735342.md)
- [CME Q3 revenue rises double digits, beats analyst estimates](https://longbridge.com/en/news/302552172.md)
- [MaxLinear Stock In Focus After New AI Optics Power Chip Launch](https://longbridge.com/en/news/305513238.md)
- [KAPA: Rising clinical costs and limited cash sharpen the need for additional financing](https://longbridge.com/en/news/305510766.md)
- [Venture Global Senior VP, Development Musser Fory Reports Sale of $6.58 Million in Common Shares](https://longbridge.com/en/news/305510722.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**